US to impose 100% tariffs on generic pharma
President Donald Trump said the U.S. will impose 100% tariffs on imported generic pharmaceuticals, with zero tariffs for two years starting now, then 100% for one year from Aug. 1, 2028, and 200% thereafter. Companies must relocate manufacturing to the U.S. within the window. Trump said branded and patented drug tariffs are unchanged. Major firms cited include Pfizer, Eli Lilly, and Novo Nordisk.
How this was made
The 30-second read
Why it matters
The policy is designed to reshoring generic manufacturing, but analysts question feasibility and cost math, and the article flags potential affordability and access concerns.
Market read
Traders should focus on which pharma companies have exemptions, which products are classified as generics, and whether supply chains can realistically shift before the tariff step-ups.
What to watch
The article notes relocation is costly and may exceed the two-year window, but it does not quantify which firms can re-route production, secure exemptions, or pass through costs to maintain demand.
Background
The article describes a new U.S. tariff plan for generic pharmaceuticals, with zero tariffs for two years and then a step-up to 100% and 200% after specified dates.
Ticker impact
The article says major drugmakers including Pfizer have struck deals under “most favored nation” to lower drug prices and exempt them from tariffs for three years.
Moderate volatility risk around tariff headlines, with limited immediate downside if exemptions hold.
The text links Pfizer to tariff-exemption deals, implying mitigated impact, but does not quantify exposure or confirm exemption scope for all products.
The article lists Eli Lilly as having struck deals to lower drug prices and exempt them from tariffs for three years under the “most favored nation” policy.
Likely headline-driven moves rather than a clear directional repricing from this article alone.
The article provides a deal/exemption claim but no details on whether Lilly’s exposure is to generics or how the two-year/100% schedule interacts with the exemption.
The article names Novo Nordisk as part of major pharmaceutical companies that have deals to lower drug prices and exempt them from tariffs for three years.
Low-to-moderate impact; expect sensitivity to policy updates rather than a definitive repricing.
The article’s only Lilly/Pfizer/Novo Nordisk linkage is the three-year exemption deal, without specifying product categories or generic manufacturing exposure.
The article says Teva Pharmaceutical Industries and Viatris told it is too early to assess implications of the new generic-pharma tariff plan.
Potential downside bias if tariffs raise landed costs or disrupt supply, though timing depends on relocation feasibility.
The article does not state Teva’s specific exposure, but it explicitly flags Teva as assessing implications and highlights the 2-year window and potential 100% tariff escalation.
The article states Viatris said it is too early to assess the implications of the U.S. imposing 100% tariffs on imported generic pharmaceuticals.
Headline-driven downside risk until the company clarifies which products and supply chains are covered.
The article provides a direct company quote about uncertainty but no quantified exposure; still, the tariff schedule is a clear cost/margin variable.
Market effects
Generic drug importers and manufacturers with cross-border supply chains face a step-up in tariff cost risk, potentially reshaping U.S. generic pricing and sourcing.
India-focused generic exporters are highlighted as the most exposed, with potential pressure to renegotiate or diversify export routes.
Active ingredient supply chains (notably China-dominated inputs) may face second-order cost effects if U.S. tariffs propagate through formulation economics.
Counterpoint
If “most favored nation” exemptions and product-category carve-outs expand, the effective tariff burden for major branded/generic players could be far lower than the headline 100% suggests.
Key entities
- personDonald Trump
Announced the generic-pharma tariff schedule and the two-year window to shift production to the U.S.
- companyEli Lilly
Named as having struck deals to lower drug prices and exempt them from tariffs for three years.
- companyPfizer
Named as having struck deals to lower drug prices and exempt them from tariffs for three years.
- companyNovo Nordisk
Named as having struck deals to lower drug prices and exempt them from tariffs for three years.
- companySandoz Group
CEO warned steep tariffs could make drugs more expensive and limit access.
